title: Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
abstract: We investigated alterations in nerve growth factor (NGF) and ciliary neurotrophic factor (CNTF) contents during treatment with epalrestat, an aldose reductase inhibitor (ARI), on streptozotocin (STZ)-induced diabetic neuropathy in rats. Diabetic rats showed a statistically significant reduction in H-wave-related sensory nerve conduction velocity (HSNCV) and in NGF content in sciatic nerves during the experiment of 8 weeks. No reduction in the CNTF content in sciatic nerves was seen in the diabetic rats. The epalrestat treatment, which started 4 weeks after STZ injection, resulted in a significantly greater NGF content and faster HSNCV than those in untreated diabetic rats. But no statistically significant alterations of motor nerve conduction velocity (MNCV) or CNTF content were seen during the treatment. ARI showed the stimulating effect for NGF synthesis/secretion in rat Schwann cell culture in vitro. These findings suggest that decreased levels of NGF in diabetic sciatic nerves may be involved in the pathogenesis of diabetic neuropathy in these rats and further show that epalrestat treatment can be useful for the treatment of diabetic neuropathy through NGF-induction in Schwann cells and/or inhibition of the polyol pathway.
authors.affiliation: Division of Neurology, Department of Internal Medicine, Miyazaki Medical College, 5200 Kihara, Kiyotake-cho, Miyazaki, 889-16, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ohi
authors.forename: K
authors.initials: K
authors.lastname: Saita
authors.forename: S
authors.initials: S
authors.lastname: Furukawa
authors.forename: M
authors.initials: M
authors.lastname: Ohta
authors.forename: K
authors.initials: K
authors.lastname: Hayashi
authors.forename: S
authors.initials: S
authors.lastname: Matsukura
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D002396:Catechols / Q000494:pharmacology; D002478:Cells, Cultured; D020934:Ciliary Neurotrophic Factor; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000378:metabolism*; D004594:Electrophysiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D009414:Nerve Growth Factors / Q000096:biosynthesis / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000096:biosynthesis / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012236:Rhodanine / Q000031:analogs & derivatives / Q000494:pharmacology; D012583:Schwann Cells / Q000166:cytology / Q000187:drug effects / Q000201:enzymology; D012584:Sciatic Nerve / Q000737:chemistry / Q000166:cytology / Q000502:physiology; D053778:Thiazolidines
chemical_list: D002396:Catechols; D020934:Ciliary Neurotrophic Factor; D004791:Enzyme Inhibitors; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D053778:Thiazolidines; C018599:4-methylcatechol; C038131:epalrestat; D012236:Rhodanine; D000449:Aldehyde Reductase